Electra_Logo

Electra Therapeutics to Present Clinical Data for ELA026 at the American Society of Hematology (ASH) 2023 Annual Meeting

Company to reveal first clinical data from Phase 1b study of ELA026, its lead product candidate for life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH) SOUTH SAN FRANCISCO, CA, November 2, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets, announced today that the company will present the initial […]